GLP1R and chronic kidney disease: Differences in baseline characteristics between trials may also influence findings, as GLP-1 RAs were frequently studied in patients with atherosclerotic cardiovascular disease, whereas SGLT2 inhibitors showed greater efficacy in those with heart failure and chronic kidney disease.